LAG3:弥漫性大B细胞淋巴瘤中多种淋巴细胞亚群表达的新型免疫检查点
在309例接受标准化疗免疫治疗的弥漫性大B细胞淋巴瘤(DLBCL)患者中,LAG3高表达于CD4+调节性T细胞和CD8+肿瘤浸润淋巴细胞,并可见于部分恶性B细胞和肿瘤相关巨噬细胞;LAG3高表达与较差生存相关,且独立于细胞来源和国际预后指数。
要点
- LAG3在DLBCL的CD4+调节性T细胞和CD8+肿瘤浸润淋巴细胞上高表达,常与PD-1、TIM-3共表达。
- LAG3高表达与较差生存相关,独立于细胞来源和国际预后指数。
- PD-L1高表达患者中LAG3高表达的可能性为五倍,LAG3高/PD-L1高患者生存更差。
核心结论
- LAG3高表达与DLBCL患者较差预后相关,且独立于常规预后指标。
研究设计与样本
- 研究纳入309例接受标准化疗免疫治疗的DLBCL患者,采用数字基因表达检测LAG3,并通过免疫组化和流式细胞术确定LAG3蛋白的细胞分布。
主要发现
- 在肿瘤浸润淋巴细胞中,LAG3在CD4+调节性T细胞上表达最高,在CD8+ T细胞上的表达也高于CD4+非调节性T细胞(均P = .008)。
- LAG3高表达肿瘤浸润淋巴细胞富集PD-1和TIM-3。
- LAG3也表达于部分恶性B细胞,这些患者活检组织中LAG3信使RNA显著更高(P = .03)。
- 在发现/验证队列中,LAG3高基因表达与较差生存相关,独立于细胞来源和国际预后指数。
- PD-L1高表达患者为LAG3高表达的可能性是五倍(P < .0001);LAG3高/PD-L1高患者与LAG3低/PD-L1高患者相比,无进展生存期(P = .011)和总生存期(P = .005)更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact of LAG3 digital gene expression was tested in 309 patients with DLBCL treated with standard chemoimmunotherapy. Cellular distribution of LAG3 protein was determined by immunohistochemistry and flow cytometry. In tumor-infiltrating lymphocytes (TILs), LAG3 expression was highest on CD4+ regulatory T cells (Tregs) and was also highly expressed on CD8+ T cells compared with CD4+ non-Tregs (both P = .008). LAG3high TILs were enriched in PD-1 and TIM-3. LAG3 was also expressed on a proportion of malignant B cells, and these patients had significantly higher LAG3 messenger RNA in their biopsies (P = .03). LAG3high gene expression was associated with inferior survival in discovery/validation cohorts, independent of cell of origin and the international prognostic index. Patients who were PD-L1high were fivefold more likely to be LAG3high (P < .0001). Patients who were LAG3high/PD-L1high had an inferior progression-free survival (P = .011) and overall survival (P = .005) compared with patients who were LAG3low/PD-L1high. Digital spatial protein analysis confirms LAG3 expression on T cells and, surprisingly, tumor-associated macrophages (TAMs) at higher levels than found on CD20+ B cells in the tumor microenvironment. LAG3 is frequently expressed on CD4+ Tregs and CD8+ TILs, typically with other immune checkpoints, and is also present in a proportion of malignant B cells in DLBCL and in areas enriched for TAMs. LAG3high expression is associated with poor outcome independent of conventional prognosticators.
引用
- Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32267932. doi:10.1182/bloodadvances.2019001390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。